Humacyte Stock Price To Sales
HUMAW Stock | USD 1.47 0.03 2.00% |
Humacyte fundamentals help investors to digest information that contributes to Humacyte's financial success or failures. It also enables traders to predict the movement of Humacyte Stock. The fundamental analysis module provides a way to measure Humacyte's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Humacyte stock.
Last Reported | Projected for Next Year | ||
Price To Sales Ratio | 125.04 | 96.95 |
Humacyte | Price To Sales |
Humacyte Company Price To Sales Analysis
Humacyte's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Humacyte Price To Sales | 96.95 |
Most of Humacyte's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Humacyte is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Humacyte Price To Sales Driver Correlations
Understanding the fundamental principles of building solid financial models for Humacyte is extremely important. It helps to project a fair market value of Humacyte Stock properly, considering its historical fundamentals such as Price To Sales. Since Humacyte's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Humacyte's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Humacyte's interrelated accounts and indicators.
Click cells to compare fundamentals
Humacyte Price To Sales Historical Pattern
Today, most investors in Humacyte Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Humacyte's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's price to sales growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Humacyte price to sales as a starting point in their analysis.
Humacyte Price To Sales |
Timeline |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Competition |
Humacyte Price To Sales Ratio
Price To Sales Ratio |
|
Did you try this?
Run Options Analysis Now
Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios |
All Next | Launch Module |
Humacyte Fundamentals
Return On Equity | -8.51 | ||||
Return On Asset | -0.53 | ||||
Number Of Shares Shorted | 286 | ||||
EBITDA | (96.46 M) | ||||
Net Income | (110.78 M) | ||||
Total Debt | 58.11 M | ||||
Book Value Per Share | (0.53) X | ||||
Cash Flow From Operations | (73.31 M) | ||||
Earnings Per Share | (3.16) X | ||||
Number Of Employees | 183 | ||||
Beta | 1.47 | ||||
Total Asset | 128.22 M | ||||
Retained Earnings | (537.31 M) | ||||
Working Capital | 64.83 M | ||||
Net Asset | 128.22 M |
About Humacyte Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Humacyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Humacyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Humacyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Humacyte Stock Analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.